207 related articles for article (PubMed ID: 8149466)
1. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes.
Lim CK; Yuan ZX; Lamb JH; White IN; De Matteis F; Smith LL
Carcinogenesis; 1994 Apr; 15(4):589-93. PubMed ID: 8149466
[TBL] [Abstract][Full Text] [Related]
2. On-line high-performance liquid chromatographic-electrospray ionization mass spectrometric method for the study of tamoxifen metabolism.
Jones RM; Yuan ZX; Lamb JH; Lim CK
J Chromatogr A; 1996 Jan; 722(1-2):249-55. PubMed ID: 9019299
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen metabolism in rat liver microsomes: identification of a dimeric metabolite derived from free radical intermediates by liquid chromatography/mass spectrometry.
Jones RM; Yuan ZX; Lim CK
Rapid Commun Mass Spectrom; 1999; 13(4):211-5. PubMed ID: 10097399
[TBL] [Abstract][Full Text] [Related]
4. Aspects of metabolism of tamoxifen by rat liver microsomes. Identification of a new metabolite: E-1-[4-(2-dimethylaminoethoxy)-phenyl]-1, 2-diphenyl-1-buten-3-ol N-oxide.
McCague R; Seago A
Biochem Pharmacol; 1986 Mar; 35(5):827-34. PubMed ID: 3954788
[TBL] [Abstract][Full Text] [Related]
5. The deuterium isotope effect for the alpha-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of [D5-ethyl]tamoxifen.
Jarman M; Poon GK; Rowlands MG; Grimshaw RM; Horton MN; Potter GA; McCague R
Carcinogenesis; 1995 Apr; 16(4):683-8. PubMed ID: 7728943
[TBL] [Abstract][Full Text] [Related]
6. Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.
Dehal SS; Kupfer D
Cancer Res; 1996 Mar; 56(6):1283-90. PubMed ID: 8640815
[TBL] [Abstract][Full Text] [Related]
7. Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts.
Boocock DJ; Maggs JL; Brown K; White IN; Park BK
Carcinogenesis; 2000 Oct; 21(10):1851-8. PubMed ID: 11023543
[TBL] [Abstract][Full Text] [Related]
8. Effect of inhibitors on the biotransformation of tamoxifen by female rat and mouse liver slices and homogenates.
Jordan CG; Brown K; Beedham C; Brown JE
Drug Metabol Drug Interact; 1999; 15(4):239-58. PubMed ID: 10716039
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations.
Egorin MJ; Rosen DM; Wolff JH; Callery PS; Musser SM; Eiseman JL
Cancer Res; 1998 Jun; 58(11):2385-96. PubMed ID: 9622079
[TBL] [Abstract][Full Text] [Related]
10. Species differences in metabolism of panomifene, an analogue of tamoxifen.
Monostory K; Jemnitz K; Vereczkey L; Czira G
Drug Metab Dispos; 1997 Dec; 25(12):1370-8. PubMed ID: 9394026
[TBL] [Abstract][Full Text] [Related]
11. Toremifene metabolism in rat, mouse and human liver microsomes: identification of alpha-hydroxytoremifene by LC-MS.
Jones RM; Lim CK
Biomed Chromatogr; 2002 Aug; 16(5):361-3. PubMed ID: 12210510
[TBL] [Abstract][Full Text] [Related]
12. Identification and mechanism of formation of potentially genotoxic metabolites of tamoxifen: study by LC-MS/MS.
Lim CK; Yuan ZX; Jones RM; White IN; Smith LL
J Pharm Biomed Anal; 1997 Jun; 15(9-10):1335-42. PubMed ID: 9226561
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation.
Mani C; Hodgson E; Kupfer D
Drug Metab Dispos; 1993; 21(4):657-61. PubMed ID: 8104125
[TBL] [Abstract][Full Text] [Related]
14. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
15. Differences in metabolite-mediated toxicity of tamoxifen in rodents versus humans elucidated with DNA/microsome electro-optical arrays and nanoreactors.
Zhao L; Krishnan S; Zhang Y; Schenkman JB; Rusling JF
Chem Res Toxicol; 2009 Feb; 22(2):341-7. PubMed ID: 19166339
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone.
Zhang F; Fan PW; Liu X; Shen L; van Breemen RB; Bolton JL
Chem Res Toxicol; 2000 Jan; 13(1):53-62. PubMed ID: 10649967
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of tamoxifen and its uterotrophic activity.
Lyman SD; Jordan VC
Biochem Pharmacol; 1985 Aug; 34(15):2787-94. PubMed ID: 4015715
[TBL] [Abstract][Full Text] [Related]
18. Some chemical and biochemical aspects of liver microsomal metabolism of tamoxifen.
Ruenitz PC; Bagley JR; Pape CW
Drug Metab Dispos; 1984; 12(4):478-83. PubMed ID: 6148216
[TBL] [Abstract][Full Text] [Related]
19. In vitro metabolism of 4-vinylcyclohexene in rat and mouse liver, lung, and ovary.
Keller DA; Carpenter SC; Cagen SZ; Reitman FA
Toxicol Appl Pharmacol; 1997 May; 144(1):36-44. PubMed ID: 9169067
[TBL] [Abstract][Full Text] [Related]
20. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.
Robinson SP; Langan-Fahey SM; Johnson DA; Jordan VC
Drug Metab Dispos; 1991; 19(1):36-43. PubMed ID: 1673419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
